ArticleScientific reports2016

The Novel Antitubulin Agent TR-764 Strongly Reduces Tumor Vasculature and Inhibits HIF-1α Activation.

Elena Porcù et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.